Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

Authors

Ajay K Gopal, University of Washington
Nancy L Bartlett, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

7-8-2025

Volume

9

Issue

13

First Page

3383

Last Page

3394

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2024015086

Rights and Permissions

Gopal AK, Armand P, Neelapu SS, Bartlett NL, Spurgeon SE, Kuruvilla J, Savage KJ, Leonard JP, Gelb AB, Ahmed N, Dong S, Bathena SP, Suryawanshi R, Wu JQ, Wang S, Gladstone DE. Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022. Blood Adv. 2025 Jul 8;9(13):3383-3394. doi: 10.1182/bloodadvances.2024015086. © 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Gopal, Ajay K; Bartlett, Nancy L; and et al., "Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022." Blood Advances. 9, 13. 3383 - 3394. (2025).
https://digitalcommons.wustl.edu/oa_4/5894

Additional Links

Supplemental material is available for this article at publisher site.